Recursion Pharmaceuticals (RXRX) has shared an update.
Recursion Pharmaceuticals and Exscientia have announced a proposed transaction that will be outlined in a forthcoming joint proxy statement. This strategic move will be subject to shareholder approval and other customary conditions. The transaction, if completed, will combine the strengths of both companies, aiming to accelerate the discovery and development of novel therapeutics. The joint proxy statement will provide full details of the transaction, including risks and benefits, and will be filed with the SEC for review by both companies’ shareholders. Security holders are advised to read the definitive joint proxy statement once available, as it will contain important information about the proposed transaction.
See more data about RXRX stock on TipRanks’ Stock Analysis page.
